Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ponseti, J. M.
Right arrow Articles by Armengol, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ponseti, J. M.
Right arrow Articles by Armengol, M.
Related Collections
Right arrowRelated Article
NEUROLOGY 2005;64:1641-1643
© 2005 American Academy of Neurology
Brief Communications

Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis

J. M. Ponseti, MD, PhD, J. Azem, MD, J. M. Fort, MD, PhD, M. López-Cano, MD, PhD, R. Vilallonga, MD, M. Buera, MD, C. Cervera, MD, PhD and M. Armengol, MD, PhD

From the Myasthenia Gravis Unit, Department of Surgery (Drs. Ponseti, Azem, Fort, López-Cano, Vilallonga, Buera, and Armengol) and Neurology Service (Dr. Cervera), Hospital General Universitari Vall d’Hebron, Autonomous University of Barcelona, Barcelona, Spain.

Address correspondence and reprint requests to Dr. José M. Ponseti, Unit of Myasthenia Gravis, Department of Surgery, Hospital General Universitari Vall d’Hebron, Passeig Vall d’Hebron 119-129, E-08035 Barcelona, Spain; e-mail: jmponseti{at}vhebron.net and 5012jpb{at}comb.es

Seventy-nine patients with cyclosporine- and prednisone-dependent myasthenia gravis (MG) after thymectomy received tacrolimus for a mean of 2.5 ± 0.8 years. Prednisone was withdrawn in all but two patients. Anti-acetylcholine antibodies and MG score for disease severity decreased significantly and muscular strength increased by 39%. Complete stable remission was achieved in 5% of patients and pharmacologic remission in 87.3%. All patients resumed full activities of daily living.

Received October 28, 2004. Accepted in final form January 26, 2005.


Related Article

May 10 Highlights
Neurology 2005 64: 1492-1493. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 NeurologyHome page
D. B. Sanders, J. A. Aarli, G. R. Cutter, A. Jaretzki III, H. J. Kaminski, L. H. Phillips II, J .M. Ponseti, J . Azem, J .M. Fort, M . Lopez-Cano, et al.
Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis
Neurology, March 28, 2006; 66(6): 954 - 955.
[Full Text] [PDF]

Correspondence:

Read all Correspondence

Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis
Donald B. Sanders, et al.
Neurology Online, 15 Sep 2005 [Full text]
Reply to Sanders et al
José M. Ponseti, et al.
Neurology Online, 15 Sep 2005 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.